Last reviewed · How we verify
NCT03895528
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
trial testing Lonafarnib in Progeria. Approved for marketing.
Quick facts
| Lead sponsor | Eiger BioPharmaceuticals |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Lonafarnib (LONAFARNIB) — full drug profile →
Conditions studied
Sponsor
Eiger BioPharmaceuticals — full company profile →
Who can join
12 Months and older, any sex, with Progeria or HGPS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lonafarnib: First Approval.
Dhillon S. · · 2021 · cited 88× · PMID 33590450 · DOI 10.1007/s40265-020-01464-z
Verify or expand the search:
- PubMed search for NCT03895528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lonafarnib
Trials testing the same drug.
- NCT05229991 — Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection · Phase 3 · unknown
- NCT03719313 — Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a · Phase 3 · completed
- NCT03600714 — Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon · Phase 2 · completed
- NCT02511431 — Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir · Phase 2 · completed
- NCT00102648 — Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Pr · Phase 1 · active not recruiting
Other Eiger BioPharmaceuticals trials
Trials by the same sponsor.
- NCT05070364 — Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV · Phase 3 · unknown
- NCT03719313 — Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a · Phase 3 · completed
- NCT03373435 — Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia · Phase 2 · completed
- NCT02765802 — A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection · Phase 2 · completed
- NCT02968641 — A Study of Lonafarnib With or Without Ritonavir in Patients With HDV · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03895528 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eiger BioPharmaceuticals
- Last refreshed: 15 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03895528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing